Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2000 May 20;320(7246):1368-73.
doi: 10.1136/bmj.320.7246.1368.

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)

S Shrewsbury  1 , S Pyke, M Britton
Affiliations
Meta-Analysis

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)

S Shrewsbury et al. BMJ. .

Abstract

Objective: To examine the benefits of adding salmeterol compared with increasing dose of inhaled corticosteroids.

Design: Systematic review of randomised, double blind clinical trials. Independent data extraction and validation with summary data from study reports and manuscripts. Fixed and random effects analyses.

Setting: EMBASE, Medline, and GlaxoWellcome internal clinical study registers.

Main outcome measures: Efficacy and exacerbations.

Results: Among 2055 trials of treatment with salmeterol, there were nine parallel group trials of >/=12 weeks with 3685 symptomatic patients aged >/=12 years taking inhaled steroid in primary or secondary care. Compared with response to increased steroids, in patients receiving salmeterol morning peak expiratory flow was greater at three months (difference 22.4 (95% confidence interval 15.0 to 30.0) litre/min, P<0.001) and six months (27.7 (19.0 to 36.4) litre/min, P<0.001). Forced expiratory volume in one second (FEV(1)) was also increased at three months (0.10 (0.04 to 0.16) litres, P<0.001) and six months (0.08 (0.02 to 0.14) litres, P<0.01), as were mean percentage of days and nights without symptoms (three months: days-12% (9% to 15%), nights-5% (3% to 7%); six months: days-15% (12% to 18%), nights-5% (3% to 7%); all P<0.001) and mean percentage of days and nights without need for rescue treatment (three months: days-17% (14% to 20%), nights-9% (7% to 11%); six months: days-20% (17 to 23%), nights-8% (6% to 11%); all P<0.001). Fewer patients experienced any exacerbation with salmeterol (difference 2.73% (0.43% to 5.04%), P=0. 02), and the proportion of patients with moderate or severe exacerbations was also lower (2.42% (0.24% to 4.60%), P=0.03).

Conclusions: Addition of salmeterol in symptomatic patients aged 12 and over on low to moderate doses of inhaled steroid gives improved lung function and increased number of days and nights without symptoms or need for rescue treatment with no increase in exacerbations of any severity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results of search of EMBASE, Medline, and GlaxoWellcome clinical studies databases for work on salmeterol/Serevent
Figure 2
Figure 2
Study difference in proportion of patients with one or more exacerbations
Figure 3
Figure 3
Difference in proportion of patients with one or more exacerbations (with 95% confidence intervals). Positive differences indicate treatment benefit with addition of salmeterol
See this image and copyright information in PMC

Comment in

References

    1. British Guidelines on Asthma Management. 1995 review and position statement. Thorax. 1997;52(suppl 1):1–21. - PubMed
    1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroids in asthma patients. Lancet. 1994;344:523–529. - PubMed
    1. Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med. 1997;337:1405–1411. - PubMed
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials. 1986;7:177–188. - PubMed
    1. Egger M, Smith GD. Meta-analysis bias in location and selection of studies. BMJ. 1998;16:61–66. - PMC - PubMed

Publication types

MeSH terms